University of Galway to lead multi-institutional study in Europe, supported by Joint Programme Neurodegenerative Disease Research

A research project aimed at advancing the understanding and treatment of neurodegenerative disorders has received €1.1 million in funding support by the European Union through the Joint Programme on Neurodegenerative Disease Research (JPND).

The funding will spearhead a collaborative project, led by researchers at University of Galway, in partnership with institutions in Poland, Italy and Turkey.

Neurodegenerative disorders, including Alzheimer's, Parkinson's, and Huntington's diseases, present a significant challenge due to their debilitating nature. Marked by the gradual deterioration of nerve cells, these conditions severely impact a person’s quality of life and place a substantial burden on patients, families, and healthcare systems.

The research will be led by Dr Kasia Whysall with Dr Leo Quinlan, Principal Investigators and Associate Professors at the College of Medicine, Nursing and Health Sciences at University of Galway.

Dr Whysall said: “This research endeavours to seek to unravel the complex mechanisms underlying neurodegeneration, with a particular focus on Alzheimer’s Disease.

“Specific proteins which accumulate as a result of the disease have been studied, however their regulation poses challenges.

"This project aims to uncover valuable insights into the early pathological processes driving neurodegeneration.

"Our research suggests that early changes in the function of enzymes known as V-ATPase, and how this affects lysosomes – a type of recycling centre in the body that helps cells function properly, could be a key target for intervention to restore metabolic balance. We also found that damage to these cell parts might make neurons more vulnerable, supporting our investigation into treatment strategies that target gene regulation."

The research will be driven by the pressing need for early detection and effective interventions, and will employ cutting-edge technologies and collaborative partnerships to explore novel pathways for development of treatments for Alzheimer’s disease. Central to the research will be the exploration of emerging biomarkers, including micro RNAs (miRs) and extracellular vesicles associated with these disorders and which hold promise as non-invasive indicators of disease onset and progression.

            Dr Quinlan said: “Our goal is not only to identify potential biomarkers for early diagnosis, but also to elucidate the underlying mechanisms of neurodegenerative diseases. By combining our research with innovative therapeutic strategies, we hope to make significant strides towards improving the lives of individuals affected by these devastating conditions.”

            Professor Martin O’Donnell, Executive Dean for the College of Medicine, Nursing and Health Sciences at University of Galway, said: “In addition to its potential implications for future clinical practice, this project is an opportunity to transform the landscape of neurodegenerative research, offering new avenues for targeting interventions and personalised treatments. The research partnerships established as part of this research underscores the importance of global cooperation in addressing pressing health challenges.”

Ends